23andme

Also: Convey Health Solutions seeks $186 million in its NYSE debut.   

The deal values 23andMe at approximately $3.5 billion through the combination of stock and cash financing.  

Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.

Sequoia Capital and NewView Capital participated in the latest funding round. 

While the company's new 510(k) cuts down some of the burden, consumers are still advised to consult their healthcare provider before making any changes to their treatments.

The cuts equal a 14% reduction in the consumer genomic company's workforce. 

Also: Khosla heir calls digital health investment a big disappointment; Humana and Philips partner on MA member monitoring.

The DnaNudge pop-ups aim to help Waitrose and John Lewis customers make healthier food choices.

Erin Trimble of 23andMe touches on the value of polygenic risk scores, how to use genetic information to improve health and the importance of equipping primary care providers to talk with their patients about genetics.

The Israel-based company is offering 11 genetic risk tests, three polygenic risk tests and 15 carrier status reports.